Document:

Exhibit 10.4

                        ROYALTY AND INVESTMENT AGREEMENT
                        MILLENNIUM BIOTECHNOLOGIES, INC.

      This Investment Agreement (this "Agreement") is entered into as of January
11, 2001 by and between Millennium Biotechnologies, Inc., a Delaware corporation
(the "Company") and Jane Swon (the "Investor").

                                    RECITALS

      WHEREAS,  the Company is a recently formed  development  stage  enterprise
which expects to develop,  produce and market  nutraceutical  supplements  which
compliment traditional therapeutic treatment of infectious diseases;

      WHEREAS,  the  Investor for an  aggregate  purchase  price of $25,000 (the
"Securities  Purchase  Price")  has agreed to purchase  3,000,000  shares of the
Company's  common stock,  $.00001 par value,  and 800,000 five year common stock
purchase warrants exercisable at $.50 per share;

      WHEREAS,  in  consideration  of an additional  investment in the amount of
$25,000 (the "Royalty Investment") the Company has agreed to pay to the Investor
a perpetual royalty based upon sales of the Company's products.

                                    AGREEMENT

      NOW,  THEREFORE,  for good and  valuable  consideration,  the  receipt and
sufficiency  of which are  hereby  acknowledged,  the  parties  hereto  agree as
follows:

      Section 1.  Issuance  of Shares and  Warrants.  The  Company  shall,  upon
execution of this Agreement and receipt of the Securities  Purchase Price, issue
to the Investor  (i)  3,000,000  shares of common  stock  $.00001 par value (the
"Shares")  which Shares shall be fully paid and non  assessable and (ii) 800,000
five year common  stock  purchase  warrants  with an exercise  price of $.50 per
share (the "Warrants"). The Shares and the Warrants are collectively referred to
herein as the "Securities".

      Section 2.  Royalty.  In  consideration  of the  Royalty  Investment,  the
Company shall pay to the Investor,  a royalty  ("Royalty")  which shall be based
upon  (a) sale of the  Company's  initial  product  offering  under  the name of
Resurgex(TM)  which  Royalty shall equal the product of .033 and the gross sales
of Resurgex(TM) (net of discounts and returns) in each calendar quarter; and (b)
sale of any additional  products  ("Additional  Products") for which the Royalty
shall equal the product of .033 and gross profit  ("Gross  Profit") from sale of
Additional  Products  in  each  calendar  quarter.  Gross  Profit  from  sale of
Additional  Products  shall mean the gross sales (net of

<PAGE>

discounts and returns)  less the direct cost of  production  of such  Additional
Products.  Direct cost of  production  shall mean the cost to the Company of raw
materials,  labor,  shipping  and  packaging.  For purposes of  calculating  the
Royalty,  a sale of Resurgex(TM) or Additional  Products of the Company shall be
deemed to have been  consummated upon receipt of payment  therefor.  The Royalty
shall be payable within thirty days  following the end of each calendar  quarter
with respect to the sales completed during such calendar quarter.  The Company's
obligation to pay the Royalty shall be perpetual. In the event the Company shall
enter into a joint venture,  partnership  or other form of  arrangement  for the
manufacture, sale or marketing of Resurgex(TM) or the Additional Products, or in
the event the Company shall license or sell any rights to any such products, the
Company shall remain liable to the Investor for the payment of the Royalty based
upon the gross sales price of  Resurgex(TM)  or the Gross  Profit of  Additional
Products  received  by any  such  licensee,  joint  venture,  partner  or  other
successor to the Company.

      Section 3.  Representations  and  Warranties  of the Company.  The Company
represents and warrants to the Investor as follows:

            (a)  Organization  and  Standing.The  Company is a corporation  duly
organized,  validly existing and in good standing under the laws of the State of
Delaware.  The  Company is  qualified  as a foreign  corporation  and is in good
standing in each jurisdiction in which the conduct of its business or the assets
and properties owned or leased by it require such qualification.

            (b)  Authorization.  The Company is fully authorized to execute this
Agreement, and to complete the transactions  contemplated herein. This Agreement
constitutes the valid and binding  obligation of the Company  enforceable by the
Investor against the Company in accordance with its terms.

            (c) Binding  Agreement.  This  Agreement  has been duly executed and
delivered and constitutes a legal, valid and binding  obligation  enforceable in
accordance with its terms.

            (d) No Conflicts.  The execution and delivery of this  Agreement and
the issuance of the Securities to the Investor as  contemplated  hereby will not
(i)  require  any  consent  authorization  or  approval  of or  filing  with any
governmental  entity or third party,  or (ii) result in any  violation of, be in
conflict  with or  constitute  a default  under,  the  charter or by-laws of the
Company  or  any  law,  statute,  regulation,  ordinance,  contract,  agreement,
instrument,  judgment,  decree  or order to which the  Company  is a party or by
which the Company is bound.

            (e) Compliance with Securities Laws.  Subject to the accuracy of the
representations  and  warranties of the Investor  contained in Section 3 hereof,
the  issuance of the  Securities  to the  Investor  hereunder is exempt from the
registration and prospectus delivery requirements of the Securities Act of 1933,
as amended (the "1933 Act"),  and any applicable  state  securities and blue sky
laws.

<PAGE>

      Section 4.  Representations  and Warranties of the Investor.  The Investor
hereby represents and warrants to the Company as follows:

            (a)  Review  of  Agreement.  THE  INVESTOR  HAS READ  CAREFULLY  AND
UNDERSTANDS  THIS  AGREEMENT  AND HAS  CONSULTED  THE  INVESTOR'S  OWN ATTORNEY,
ACCOUNTANT OR  INVESTMENT  ADVISER WITH RESPECT TO THE  INVESTMENT  CONTEMPLATED
HEREBY AND ITS SUITABILITY FOR THE INVESTOR.

            (b)  Long-Term   Investment.   The  Investor  understands  that  the
Securities have not been registered under the 1933 Act and, therefore, cannot be
resold  unless  they are  subsequently  registered  under the 1933 Act or unless
exemption from such  registration  is available;  that the Investor is obtaining
the  Securities  for  investment  for the account of the Investor and not with a
view toward resale or other distribution  thereof,  that the Investor agrees not
to resell or otherwise dispose of all or any part of the Securities  acquired by
the Investor  except as permitted by law,  including,  without  limitation,  any
regulations  under the 1933 Act; that the Company does not have any intention of
registering  the Securities  under the 1933 Act or of supplying the  information
which may be necessary to enable the Investor to sell any  Securities;  and that
Rule 144 under the 1933 Act may not be available as a basis for  exemption  from
registration of any Securities  thereunder  until at least one (1) year from the
date of acquisition of the Securities.

      Section 5.  Piggy Back  Registration  Rights.  If the  Company at any time
during the  exercise  period of the  Warrants  proposes to  register  any of its
common stock (a "Registration") under the Securities Act (other than pursuant to
a registration statement on Form S-4 or Form S-8 or any successor forms thereto,
in  connection  with an offer  made  solely  to  existing  Security  holders  or
employees of the Company), for sale to the public in a Public Offering, it will,
on each  such  occasion,  give  prompt  written  notice to the  Investor  of its
intention do do so. Upon the written  request of the Investor to  include-either
the Shares, the shares underlying execution of the Warrant or if the Warrant has
been  previously   exercised,   the  shares   delivered  to  the  Investor  (the
"Registrable Securities") under such registration statement (which request shall
be made within  fifteen (15)  Business Days after the receipt of any such notice
and shall specify the Registrable  Securities  intended to be disposed of by the
Investor),   the  Company  will  effect  the  registration  of  the  Registrable
Securities as part of the Registration.

      Section 6. Restrictions on Transfer.

            Legends.   The  Investor   hereby   agrees  that  each   outstanding
certificate  representing  the  Securities  acquired  hereunder  shall  bear the
following legend:

THESE  SECURITIES HAVE NOT BEEN REGISTERED  UNDER THE SECURITIES ACT OF 1933, AS
AMENDED  (THE  "SECURITIES  ACT"),  AND  MAY  NOT  BE  OFFERED,  SOLD,  PLEDGED,
HYPOTHECATED,  ASSIGNED OR  TRANSFERRED  EXCEPT (i)  PURSUANT TO A  REGISTRATION
STATEMENT  UNDER THE  SECURITIES  ACT WHICH HAS BECOME  EFFECTIVE AND IS CURRENT
WITH

<PAGE>

RESPECT TO THESE  SECURITIES,  OR (ii)  PURSUANT  TO A SPECIFIC  EXEMPTION  FROM
REGISTRATION UNDER THE SECURITIES ACT BUT ONLY UPON A HOLDER HEREOF FIRST HAVING
OBTAINED THE WRITTEN  OPINION OF COUNSEL TO THE  CORPORATION,  OR OTHER  COUNSEL
REASONABLY  ACCEPTABLE  TO THE  CORPORATION,  THAT THE PROPOSED  DISPOSITION  IS
CONSISTENT  WITH ALL APPLICABLE  PROVISIONS OF THE SECURITIES ACT AS WELL AS ANY
APPLICABLE "BLUE SKY" OR SIMILAR SECURITIES LAW.

      Section 7. Miscellaneous.

            (a) This  Agreement is governed by and construed in accordance  with
the  internal  laws of the State of New York  (excluding  its  conflicts of laws
principles).

            (b) The representations  and warranties  contained in this Agreement
shall survive the execution, delivery and performance of this Agreement.

            (c) This  Agreement  or any term hereof may not be amended or waived
except with the written consent of the Company and the Investor.

            (d)   Unless   otherwise    specifically    provided   herein,   all
communications  under this Agreement  shall be in writing and shall be deemed to
have been duly  given (i) on the date of  service  if served  personally  on the
party to whom notice is to be given,  (ii) on the day of transmission if sent by
facsimile transmission to the number given below, and telephonic confirmation of
receipt is obtained promptly after completion of transmission,  (iii) on the day
after delivery to Federal Express or similar overnight  courier,  or (iv) on the
fifth day after  mailing,  if mailed to the party to whom notice is to be given,
by first class mail,  registered or  certified,  postage  prepaid,  and properly
addressed, return receipt requested, to the party as follows:

            If to the Company:  Millennium Biotechnologies, Inc.
                                One Anderson Hill Road, Suite 103
                                Bernardsville, N J 07924

            If to the Investor: Jane Swon
                                5 Kerby Lane
                                Mendham, NJ 07945

            (e) This Agreement may be executed in two (2) or more  counterparts,
and with counterpart signature pages, each of which shall be deemed an original,
and all of  such  counterparts  together  constitute  but  one (1) and the  same
agreement.  One (1) or more  counterparts may be delivered by facsimile with the
same force and effect as an original.

<PAGE>

      IN WITNESS WHEREOF, the parties have executed this Investment Agreement as
of the date set forth above.

                                       MILLENNIUM BIOTECHNOLOGIES, INC.

                                       By: /s/ Jerry Swon
                                       --------------------------------------
                                       Name:  Jerry Swon
                                       Title: President

                                       /s/ Jane Swon
                                       --------------------------------------
                                       Jane SwonExhibit 10.5

                              INVESTMENT AGREEMENT
                        MILLENNIUM BIOTECHNOLOGIES, INC.

      This Investment Agreement (this "Agreement") is entered into as of January
11, 2001 by and between Millennium Biotechnologies, Inc., a Delaware corporation
(the "Company") and David Miller (the "Investor").

                                    RECITALS

      WHEREAS, the Company is a recently formed development stage enterprise
which expects to develop, produce and market nutraceutical supplements which
compliment traditional therapeutic treatment of infectious diseases;

      WHEREAS, the Investor has agreed to assign, convey and deliver to the
Company all formulations he has developed, made or created with respect to
nutraceutical supplements (the "Assignment");

      WHEREAS, in consideration of the Assignment, the Company has agreed (i) to
issue to the Investor 2,000,000 shares of the Company's common stock $.0001 par
value; and (ii) to pay to the Investor a perpetual royalty based upon the sales
of the Company's products.

                                    AGREEMENT

      NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:

      Section 1. Issuance of Shares. The Company shall, upon execution of this
Agreement, issue to the Investor 2,000,000 shares of common stock $.00001 par
value (the "Shares") which Shares shall be fully paid and non assessable.

      Section 2. Royalty. In consideration of the Assignment, the Company shall
pay to the Investor, a royalty ("Royalty") which shall be based upon (a) sale of
the Company's initial product offering under the name of Resurgex(TM) which
Royalty shall equal the product of .033 and the gross sales of Resurgex(TM) (net
of discounts and returns) in each calendar quarter; and (b) sale of any
additional products ("Additional Products") for which the Royalty shall equal
the product of .033 and gross profit ("Gross Profit") from sale of Additional
Products in each calendar quarter. Gross Profit from sale of Additional Products
shall mean the gross sales (net of discounts and returns) less the direct cost
of production of such Additional Products. Direct cost of production shall mean
the cost to the Company of raw materials, labor, shipping and packaging. For
purposes of calculating the Royalty, a sale of Resurgex(TM) or Additional
Products of the Company shall be deemed to have been consummated upon receipt of
payment therefor. The Royalty shall be payable within thirty days following the
end of each calendar quarter with respect to the sales completed during such
calendar quarter. The Company's obligation to pay the Royalty shall be
perpetual. In the event the Company shall enter into a joint venture,
partnership or other form of arrangement for the manufacture, sale or marketing
of Resurgex(TM)

<PAGE>

or the Additional Products, or in the event the Company shall license or sell
any rights to any such products, the Company shall remain liable to the Investor
for the payment of the Royalty based upon the gross sales price of Resurgex(TM)
or the Gross Profit of Additional Products received by any such licensee, joint
venture, partner or other successor to the Company.

      Section 3. Assignment. The Investor hereby assigns to the Company all of
his right, title and interest including rights to patent and copyright, in and
to all formulations, material and technology made, invented or developed by the
Investor (collectively "Inventions") which Inventions relate in any way to
nutraceutical supplements including and without limitation of the foregoing, the
formulations, devices, material and technology relating to the product known as
Resurgex(TM), and the name Resurgex. The Company is hereby granted the exclusive
right to patent and trademark any such Inventions and the Investor shall execute
all divisional, continuing and reissue applications to assist the Company, at
the Company's expense, to obtain and to enforce such patent rights in the United
States and abroad.

      Section 4. Representations and Warranties of the Company. The Company
represents and warrants to the Investor as follows:

            (a) Organization and Standing.The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware. The Company is qualified as a foreign corporation and is in good
standing in each jurisdiction in which the conduct of its business or the assets
and properties owned or leased by it require such qualification.

            (b) Authorization. The Company is fully authorized to execute this
Agreement, and to complete the transactions contemplated herein. This Agreement
constitutes the valid and binding obligation of the Company enforceable by the
Investor against the Company in accordance with its terms.

            (c) Binding Agreement. This Agreement has been duly executed and
delivered and constitutes a legal, valid and binding obligation enforceable in
accordance with its terms. (d) No Conflicts. The execution and delivery of this
Agreement and the issuance of the Securities to the Investor as contemplated
hereby will not (i) require any consent authorization or approval of or filing
with any governmental entity or third party, or (ii) result in any violation of,
be in conflict with or constitute a default under, the charter or by-laws of the
Company or any law, statute, regulation, ordinance, contract, agreement,
instrument, judgment, decree or order to which the Company is a party or by
which the Company is bound.

            (e) Compliance with Securities Laws. Subject to the accuracy of the
representations and warranties of the Investor contained in Section 3 hereof,
the issuance of the Securities to the Investor hereunder is exempt from the
registration and prospectus delivery requirements of the Securities Act of 1933,
as amended (the "1933 Act"), and any applicable state securities and blue sky
laws.

                                       2
<PAGE>

      Section 5. Representations and Warranties of the Investor. The Investor
hereby represents and warrants to the Company as follows:

            (a) Review of Agreement. THE INVESTOR HAS READ CAREFULLY AND
UNDERSTANDS THIS AGREEMENT AND HAS CONSULTED THE INVESTOR'S OWN ATTORNEY,
ACCOUNTANT OR INVESTMENT ADVISER WITH RESPECT TO THE INVESTMENT CONTEMPLATED
HEREBY AND ITS SUITABILITY FOR THE INVESTOR.

            (b) Long-Term Investment. The Investor understands that the
Securities have not been registered under the 1933 Act and, therefore, cannot be
resold unless they are subsequently registered under the 1933 Act or unless
exemption from such registration is available; that the Investor is obtaining
the Securities for investment for the account of the Investor and not with a
view toward resale or other distribution thereof, that the Investor agrees not
to resell or otherwise dispose of all or any part of the Securities acquired by
the Investor except as permitted by law, including, without limitation, any
regulations under the 1933 Act; that the Company does not have any intention of
registering the Securities under the 1933 Act or of supplying the information
which may be necessary to enable the Investor to sell any Securities; and that
Rule 144 under the 1933 Act may not be available as a basis for exemption from
registration of any Securities thereunder until at least one (1) year from the
date of acquisition of the Securities.

      Section 6. Piggy Back Registration Rights. If the Company at any time
during the exercise period of the Warrants proposes to register any of its
common stock (a Registration") under the Securities Act (other than pursuant to
a registration statement on Form S-4 or Form S-8 or any successor forms thereto,
in connection with an offer made solely to existing Security holders or
employees of the Company), for sale to the public in a Public Offering, it will,
on each such occasion, give prompt written notice to the Investor of its
intention to do so. Upon the written request of the Investor to include-either
the Shares, the shares underlying execution of the Warrant or if the Warrant has
been previously exercised, the shares delivered to the Investor - (the
"Registrable Securities") under such registration statement (which request shall
be made within fifteen (15) Business Days after the receipt of any such notice
and shall specify the Registrable Securities intended to be disposed of by the
Investor), the Company will effect the registration of the Registrable
Securities as part of the Registration.

      Section 4. Restrictions on Transfer.

            Legends. The Investor hereby agrees that each outstanding
certificate representing the Securities acquired hereunder shall bear the
following legend:

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "SECURITIES ACT"), AND MAY NOT BE OFFERED, SOLD, PLEDGED,
HYPOTHECATED, ASSIGNED OR TRANSFERRED EXCEPT (i) PURSUANT TO A REGISTRATION
STATEMENT UNDER THE

                                       3
<PAGE>

SECURITIES ACT WHICH HAS BECOME EFFECTIVE AND IS CURRENT WITH RESPECT TO THESE
SECURITIES, OR (ii) PURSUANT TO A SPECIFIC EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT BUT ONLY UPON A HOLDER HEREOF FIRST HAVING OBTAINED THE WRITTEN
OPINION OF COUNSEL TO THE CORPORATION, OR OTHER COUNSEL REASONABLY ACCEPTABLE TO
THE CORPORATION, THAT THE PROPOSED DISPOSITION IS CONSISTENT WITH ALL APPLICABLE
PROVISIONS OF THE SECURITIES ACT AS WELL AS ANY APPLICABLE "BLUE SKY" OR SIMILAR
SECURITIES LAW.

      Section 5. Miscellaneous.

            (a) This Agreement is governed by and construed in accordance with
the internal laws of the State of New York (excluding its conflicts of laws
principles).

            (b) The representations and warranties contained in this Agreement
shall survive the execution, delivery and performance of this Agreement.

            (c) This Agreement or any term hereof may not be amended or waived
except with the written consent of the Company and the Investor.

            (d) Unless otherwise specifically provided herein, all
communications under this Agreement shall be in writing and shall be deemed to
have been duly given (i) on the date of service if served personally on the
party to whom notice is to be given, (ii) on the day of transmission if sent by
facsimile transmission to the number given below, and telephonic confirmation of
receipt is obtained promptly after completion of transmission, (iii) on the day
after delivery to Federal Express or similar overnight courier, or (iv) on the
fifth day after mailing, if mailed to the party to whom notice is to be given,
by first class mail, registered or certified, postage prepaid, and properly
addressed, return receipt requested, to the party as follows:

            If to the Company:  Millennium Biotechnologies, Inc.
                                One Anderson Hill Road, Suite 103
                                Bernardsville, N J 07924

            If to the Investor: David Miller
                                1748 Monroe Avenue
                                Bronx, NY 10457

            (e) This Agreement may be executed in two (2) or more counterparts,
and with counterpart signature pages, each of which shall be deemed an original,
and all of such counterparts together constitute but one (1) and the same
agreement. One (1) or more counterparts may be delivered by facsimile with the
same force and effect as an original.

                                       4
<PAGE>

      IN WITNESS WHEREOF, the parties have executed this Investment Agreement as
of the date set forth above.

                                       MILLENNIUM BIOTECHNOLOGIES, INC.

                                       By: /s/ Jerry Swon
                                       --------------------------------------
                                       Name:  Jerry Swon
                                       Title: President

                                       By: /s/ David Miller
                                       --------------------------------------
                                       David Miller

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}]]